Advertisement

Recombinant DNA Technology for the Production of Plasma Proteins

  • W. D. Lake
  • W. R. Srigley
Part of the Developments in Hematology and Immunology book series (DIHI, volume 13)

Abstract

During the past few years we have seen an unparalleled interest and growth in applied biology. The rapid progress in this area has been largely driven by laboratory advances in monoclonal antibody and recombinant DNA (r-DNA) techniques. Most of the early efforts to apply r-DNA technology to commercial product development were directed toward the production of small peptide hormones such as interferon, insulin and growth hormone. The only r-DNA produced therapeutic agent currently on the market is the human insulin preparation sold by Eli Lilly and Company. However, many observers believe that a human growth hormone preparation produced by Genentech could be available in 1985 and a number of other therapeutic agents such as tissue plasminogen activator are presently undergoing clinical trials.

Keywords

Factor VIII Human Albumin Plasma Fractionation Large Scale Fermentation Fermentation Capacity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Andersson L-O, Serum albumin, In: Blomback B; Hanson Lft, eds. Plasma Proteins. New York. John Wiley & Sons, 1979:43–71.Google Scholar
  2. 2.
    Food and Drug Administration. FDA talk paper T83-2: Regulating recombinant DNA products, January 7, 1983, Rockville, MD,: U.S. Department of Health and Human Services Public Health Service.Google Scholar
  3. 3.
    Bui PT. Recovery and purification of biologically active polypeptides from r-DNA microorganisms. Bio/Technology 1983;Aug:488–90.CrossRefGoogle Scholar
  4. 4.
    Thomas KB, Howards MA, Koutts J. Firkin BG. Simplified Immuno- radiometric assay for factor VIII coagulant antigen. Brit J Haemat 1982;51:47–57.PubMedCrossRefGoogle Scholar
  5. 5.
    Barrowcliffe TW, Kemball-Cook G, Morris G, Holt JC, Furlong RA, Peake IR. Factor VIII related activities in therapeutic concentrates. J Lab Clin Med 1981;97:429–38.PubMedGoogle Scholar
  6. 6.
    Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982;1648–52.Google Scholar
  7. 7.
    Shapiro SS, Hultin M. Acquired inhibitors to the blood coagulation factors. Semin Thrombos Hemostas 1975;1:336–44.Google Scholar
  8. 8.
    Andersson L-0. Haemophilia B-factor (factor IX), In: Blomback B, Hanson Lft, eds. Plasma Proteins, New York. John Wiley & Sons, 1979:281–5.Google Scholar
  9. 9.
    Chase M. Genentech claims ’First1 in technology to make antibodies: Firm, City of Hope medical scientists use techniques of Genetic engineering. Wall Street Journal 1983;May 5.Google Scholar
  10. 10.
    Stackhouse R, Chandra T, Robson KJH, Woo SLC. Purification of antithrombin III mRNA and cloning of its cDNA. J Biol Chem 1983;258:703–5.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • W. D. Lake
  • W. R. Srigley

There are no affiliations available

Personalised recommendations